95%CI: from-0.09 to +0.23; P¼0.374) and women (IRD¼+0.12; 95%CI: from -0.01 to +0.25; P¼0.061) populations. In contrast, the associations between tobacco smoking prevalence and lung cancer incidence were significant in the overall (IRD¼+3.55; 95%CI: from +3.09 to +4.00; P<0.001), men (IRD¼+4.82; 95%CI: from +4.44 to +5.20; P<0.001) and women (IRD¼+3.55; 95%CI: from +3.12 to +3.99; P<0.001) populations. The difference between the observed associations of tobacco smoking prevalence with bladder vs. lung cancer incidence was significant in all examined populations (all P<0.001). Tobacco exposure accounted for an estimated 0.81%, 2.74% and 11.59% of the variation in bladder cancer incidence vs. 89.72%, 95.80% and 90.69% of the variation in lung cancer incidence in the overall, men and women populations, respectively. CONCLUSIONS: In contrast to lung cancer, our study showed that variations in tobacco smoking prevalence were not associated with the incidence trends of bladder cancer in the US population over the past half-century.
INTRODUCTION AND OBJECTIVES: Management of T1 bladder cancer (T1-BC) is a therapeutic challenge. Tumor grade is an important prognostic factor to aid in treatment decision making. Currently, the AUA guidelines advise use of WHO 2004 grade over the 1973 classification, although in the literature, neither has been proven superior over the other. In this study, we compared the prognostic value of these WHO classifications in T1-BC.
METHODS: Three uro-pathologists revised the slides of 601 primary (first diagnosis) T1-BCs from patients treated with BCG in four university hospitals between 1983 and 2006. Grade was defined according to WHO 1973 (grade 1-3) and 2004 (low-grade; LG and highgrade; HG). Association with progression-free survival (PFS) and cancer-specific survival (CSS) was analysed for each system with multivariable cox-regression models. We corrected for age, sex, multiplicity, size (>3cm vs. 3 cm) and concomitant CIS.
RESULTS: Median age was 71 (IQR 15) years and 196/601 (33%) tumors had concomitant CIS. After revision, 188 (31%) tumors were grade 2 and 413 (69%) grade 3 (WHO 1973). According to WHO 2004, 47 (8%) tumors were LG and 554 (92%) were HG. At a median follow-up of 5.9 (IQR 3.0) years, progression (cT2 and/or N1 and/or M1) occurred in 148 (25%) patients and 94 (16%) patients died of BC. Grade 3 tumors were associated with a worse PFS (HR 2.1, p<0.001) and CSS (HR 3.4, p<0.001) than grade 2 tumors. WHO 2004 grade had no prognostic value for progression (HG vs. LG HR 2.0, p¼0.077) or CSS (HG vs. LG HR 1.6, p¼0.292). The only prognostic factor for progression on multivariable analysis was WHO 1973 grade (HR 2.0, p¼0.001). Grade 3 tumors (HR 3.0, p<0.001), increasing age (HR 1.03, p¼0.003) and tumor size >3cm (HR 1.8, p¼0.008) were all independently associated with worse CSS.
CONCLUSIONS: In T1-BC, WHO 1973 grade has a strong prognostic value, whereas the 2004 system is not prognostic. The superior value of WHO 1973 grade in T1-BC suggests that the 1973 system should be recommended by clinical non-muscle-invasive BC guidelines. METHODS: Patient information was retrospectively collected in an IRB-approved protocol on patients treated for UTUC. Screening was universally performed on all patients presenting during the study period. We evaluated patient and family history (Amsterdam I and II criteria; AMS1 and AMS2, respectively), tumor immunohistochemistry (IHC) for 4 mismatch repair proteins (MMRP), tumor and normal tissue polymerase-chain reaction for microsatellite instability (MSI), and clinical genetic analysis and counseling (GAC), in those with undiagnosed LS. Patients who were AMS 2 positive, MSI positive of IHC positive were considered as presumed lynch syndrome (pLS).
Source of Funding: None
RESULTS: From 1/2013-7/2016, 101 UTUC patients without a history of LS were universally screened during clinical follow-up. A total of 15/101 (15%) patients were pLS. 7/101 (7%) patients met AMS2 criteria. 4 patients meeting AMS2 criteria had intact expression of MMRP and no MSI instability. 11 (11%) patients had either loss of one or more MMRP. There were two cases of MSI high instability, both in patients with MMRP loss. There were no cases of MSI-high instability and negative IHC. Insufficient tissue was found in 1/101 (1%) of IHC and 8/88 (9%) of MSI tests (p¼0.0164). All patients with any positive screen were referred for GAC, 5 followed-up and all 5 patients had a confirmed germline mutation. The remaining did not follow through with GAC because of financial/insurance barriers.
CONCLUSIONS: We identified 15% of universally screened UTUC as pLS at the POC using IHC and AMS2 criteria. IHC and AMS2 criteria appear to provide the most reliable screening, outperforming AMS1 and MSI. MSI is limited by requirement for normal tissue and a greater amount of tumor tissue, and can miss cases of MMRP loss, especially MSH6. Most patients did not have a personal history of a classic LS-related cancer. Our findings of a 15% rate of LS-related UTUC has significant implications for universal POC testing of UTUC patients. . 197, No. 4S, Supplement, Monday, May 15, 2017 
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